BioXcel Therapeutics Inc., commonly referred to as BTAI, is an innovative biopharmaceutical company committed to transforming the process of drug discovery and development. This US-based company utilizes artificial intelligence to identify drug candidates and related therapeutic opportunities. The advanced technology helps predict the potential of drugs, both new and existing, in curing various diseases, primarily in the fields of neuroscience and immuno-oncology.
Founded in 2007, the company's mission is to provide a paradigm shift in the treatment of serious diseases to improve and extend the lives of patients. BTAI works with an ambitious agenda to change the medical landscape by applying cutting-edge AI technology to reduce the time, cost, and risk of drug development.
BioXcel Therapeutics is behind the invention of two impressive clinical programs - BXCL501 and BXCL701. BXCL501 is an orally dissolving thin film with dexmedetomidine as the principal component aimed for the treatment of acute agitation in various neuropsychiatric indications. The drug has shown promising results in various patient populations.
On the other hand, BXCL701 - an orally administered systemic innate immune activator, has a unique combination of immuno-oncology and anti-inflammatory activities and is utilized to treat a rare form of prostate cancer and pancreatic cancer. The enterprise is also hopeful that it will be effective in treating other types of cancers.
The breakthroughs achieved by BTAI signify the power of its AI-driven approach. Its drugs in development are quite advanced in the clinical trials, validating the unique strategy of repurposing drugs by leveraging AI.
BioXcel Therapeutics Inc. is headquartered in New Haven, Connecticut and has demonstrated continuous growth since its inception. BTAI has listed on NASDAQ with a trading symbol matching the company's initials. The company is characterized by its robust R&D infrastructure supported by a highly experienced team of scientists and clinicians.
The unique blend of biopharma knowledge and artificial intelligence capabilities sets BioXcel Therapeutics apart in the industry. It has the potential to expedite the process of drug discovery and development, bring radical change to patients' experiences with pharmaceuticals, and may even alter industry standards in the future. The company remains dedicated to its mission of improving treatments for serious diseases by leveraging advanced technologies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Teva Pharmaceuticals International plans to acquire neuroscience assets from BioXcel Therapeutics for up to $125 million, including Igalmi and investigational BXCL501. This agreement stems from BioXcel Therapeutics' Chapter 11 bankruptcy proceedings, with Teva acting as the "stalking horse bidder" in a court-supervised auction. The deal aims to strengthen Teva's neuroscience portfolio and maximize stakeholder value for BioXcel.
BioXcel Therapeutics, an AI-driven biopharma firm, has filed for Chapter 11 bankruptcy protection in the U.S. The company listed liabilities between $100 million and $500 million and assets between $10 million and $50 million. This filing follows an amended credit agreement providing an additional $1.25 million in loans, and the company had previously explored strategic options including a sale or merger.
BioXcel Therapeutics is facing an August 21 deadline to secure an acceptable transaction with its Oaktree-affiliated lenders, as its current cash reserves of $13.8 million are only sufficient to fund operations through August 2026. The company has severe liquidity issues, negative working capital, and substantial doubt about its ability to continue as a going concern, despite some improvements in operating cash use and increased revenue from IGALMI. BioXcel is exploring various strategic alternatives and contingency plans, including potential debtor-in-possession financing or bankruptcy, if a suitable transaction is not completed by the deadline.